Cancer Family
Malignant Head and Neck Neoplasm
CI-CAN-00000236Explore in graph →
1,432 active trials17 approved drugs142 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000236Explore in graph →
Clinical trials
5,449 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (629)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06691776 | Feasibility of CBCT-Guided Online Adaptive Radiotherapy (FASCINATE)(FASCINATE) | recruiting | N/A | 100 | The Netherlands Cancer InstituteOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT03649048 | Low-Dose Weekly vs High-Dose Cisplatin(RADIO) | recruiting | N/A | 100 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER |
| 1 |
| Jul 31, 2025 |
| clinicaltrials |
| NCT06307015 | De-escalation of Radiation Dose in HPV-associated OPC Utilising FMISO PET (DE-RADIATE)(DE-RADIATE) | recruiting | N/A | 25 | Royal North Shore HospitalOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05894070 | The Voice as a Tool to Detect Recurrence of Laryngeal and Hypopharyngeal Cancer(VoiceDetect) | recruiting | — | 100 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06236464 | Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas | recruiting | — | 170 | National Cancer Institute, NaplesOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06805617 | A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers(I-MAC) | recruiting | Phase 2 | 35 | Glenn J. HannaOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06923826 | Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)(TROP2) | recruiting | Phase 2 | 32 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07085234 | Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC | recruiting | Phase 2 | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07085988 | Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 2 | 109 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06935188 | Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC | recruiting | Phase 2 | 98 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07072143 | An International Study on Pediatric Patients With Rare Tumors.(PARTNER) | recruiting | — | 6,250 | Azienda Ospedaliera di PadovaOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT05774483 | Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative(SECOND N0) | recruiting | N/A | 508 | Tata Memorial HospitalOTHER_GOV | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06307327 | Comparative Study of New Classification and Traditional Classification of Radioactive Oropharyngeal Mucositis | recruiting | — | 264 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07067268 | Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy | recruiting | Phase 2 | 76 | Fudan UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT05147844 | Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma | recruiting | Phase 2 | 40 | Xinqiao Hospital of ChongqingOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT07058116 | Accelerator-based BNCT (Boron Neutron Capture Therapy) for Head and Neck Carcinoma.(BNCT) | recruiting | Phase 1 | 10 | Neutron Therapeutics, LLCINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT07055841 | Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 69 | Xiuping DingOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06228079 | Adjuvant vs Surgery Only in Early-stage Recurrent NPC | recruiting | Phase 3 | 176 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT05272696 | Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC | recruiting | Phase 2 | 86 | Guangdong Provincial People's HospitalOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06676722 | SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy | recruiting | Phase 2 | 20 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT06061705 | Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies(iMonitORL) | recruiting | N/A | 100 | Fondation Hôpital Saint-JosephOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07027280 | Noninvasive Intratumor Heterogeneity Evaluation in HNSCC | recruiting | — | 700 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT07021885 | NLit and Outcomes in HNC Survivor-Caregiver Dyads | recruiting | — | 150 | University of Kansas Medical CenterOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT07019870 | Screening for Early Diagnosis of Nose Cancer | recruiting | N/A | 20,000 | National University Hospital, SingaporeOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT05740033 | Radial Forearm Donor Site Closure | recruiting | N/A | 120 | University of British ColumbiaOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT04340024 | Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients | recruiting | — | 5,000 | National Cancer Centre, SingaporeOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT05513365 | Phase II Dutasteride in Combination With CAB vs CAB in SDC(DUCT) | recruiting | Phase 2 | 26 | Radboud University Medical CenterOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06494995 | AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy | recruiting | Phase 2 | 52 | Fudan UniversityOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06849284 | To Perform a Post-market Study of the Performance of the Idylla ThyroidPrint Assay Using Clinical Samples in Predicting the Nature of Indeterminate Thyroid Nodules (ITNs) Across Multiple Centers. | recruiting | — | 100 | Royal Cornwall Hospitals TrustOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06235203 | Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC | recruiting | Phase 3 | 154 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06943820 | AK129 Combination Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 230 | AkesoINDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT07000643 | Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma | recruiting | Phase 3 | 386 | Man HuOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06148077 | Manual Therapy on Oral Opening, Swallow Function and Upper Quarter Mobility on Head and Neck Cancer Survivors(MaTeO) | recruiting | N/A | 70 | Universidad de La FronteraOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06823479 | Towards Cure Via Only Ultra-short ICB in CSCC(MATISSE 2) | recruiting | Phase 2 | 41 | The Netherlands Cancer InstituteOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06465628 | Acupressure on Xerostomia in Head and Neck Cancer Patients | recruiting | N/A | 126 | The University of Hong KongOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06321003 | SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography(SYMILIS OCT) | recruiting | — | 200 | University of PalermoOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06749899 | QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. | recruiting | Phase 3 | 580 | Sun Yat-Sen University Cancer CenterOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT06912711 | TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 2 | 70 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT06254859 | Intraoperative Neuromuscular Monitoring and Its Impact on Pre- and Postoperative Acoustic Outcomes in Thyroid Surgery | recruiting | — | 100 | Fujian Medical UniversityOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT06744296 | Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck(MRD-DUCHESS) | recruiting | — | 75 | Massachusetts Eye and Ear InfirmaryOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT05144698 | RAPA-201 Therapy of Solid Tumors | recruiting | Phase 1 / Phase 2 | 37 | Rapa Therapeutics LLCINDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT03406247 | Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma(ADJORL1) | recruiting | Phase 2 | 140 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT06540443 | Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas | recruiting | Phase 1 | 24 | MegaPro Biomedical Co. Ltd.INDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT05621837 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(Serpentine) | recruiting | — | 1,000 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT04611113 | Immunonutrition and Tolerance to Chemoradiotherapy in Patients With Head-neck Cancer | recruiting | N/A | 86 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT04875611 | Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment(NIVONASO-21) | recruiting | Phase 2 | 32 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT05348486 | FMISO-based Adaptive Radiotherapy for Head and Neck Cancer(FARHEAD) | recruiting | N/A | 120 | University Hospital OlomoucOTHER | 1 | Apr 22, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 1, 2025source: clinicaltrials